

## REVIEW ARTICLE

# Modern Therapeutic Strategies for Coronary Artery Bypass Grafting (CABG)

Stefan Klotz, Hans H. Scheld

## SUMMARY

**Introduction:** The conventional approach to coronary artery bypass grafting using extracorporeal circulation has been the standard for many decades. This review aims to evaluate novel approaches to bypass grafting in cardiac surgery. **Methods:** Selective literature review.

**Results/Discussion:** The use of extracorporeal circulation remains the goldstandard in the surgical treatment of coronary heart disease. The use of arterial bypass grafts could replace the use of venous grafts especially in young patients, because of their good long-term patency rate. Aortocoronary bypass grafting without the use of extracorporeal circulation („off-pump“) has fallen short of expectations. However, this type of operation might help to reduce perioperative morbidity in selected patients with extensive comorbidity. *Dtsch Arztebl* 2007; 104(48): A 3334–9

**Key words:** coronary artery bypass grafting, myocardial revascularization, mortality, outcome, study

Approximately 54 000 surgical myocardial revascularizations were performed in Germany in 2005. This number represents a downward trend since the year 2000 (*diagram 1*), largely owing to the increased use of interventional procedures, i.e., percutaneous balloon angioplasty (PTCA) and/or stent implantation, to treat coronary heart disease (CHD).

The aim of this review is to summarize the modern surgical treatments of CHD on the basis of a selective reading of the literature. We will deliberately not address the somewhat controversial topic of the interventional treatment of CHD with medication-coated stents (also known as drug-eluting stents, DES).

## The standard technique

The first operative treatments of CHD consisted of direct implantation of the internal thoracic artery into the hypoxic myocardium, as described by Vineberg in 1949 (e1), and resection of the stenotic coronary segment with venous interposition grafting, as described by Murray in 1952 (e2). After Gibbon introduced the heart-lung machine in 1953 (e3), Favaloro was the first to bypass stenotic coronary vessels with vein grafts in 1967 (e4). From 1971 onward, Green used the internal thoracic artery as the standard bypass graft (e5). This operative treatment of CHD, i.e., the use of the left internal thoracic artery combined with vein grafts under assisted circulation with a heart-lung machine, remains the standard in cardiac surgical clinics around the world today. The safety and efficacy of all newer techniques must be measured against it.

## Historical survival studies


The Coronary Artery Surgical Study (CASS), performed in the early 1970's, was one of the first randomized studies of bypass grafting (1). The mortality in this study was 1.1% per year. Most patients in that era did not receive any beta-blockers, aspirin, or statins. In a later study, the Coronary Artery Bypass Graft Surgery Trialists Collaboration of 1984, the mortality was 23% in 7 years (e6). As early as 1989, Loop et al. were able to demonstrate that the most important factor promoting survival was the anastomosis of the internal thoracic artery to the left anterior descending artery (LAD), rather than the use of a venous bypass alone (2). In the meta-analysis of Yusuf et al., published 10 years later, the 7-year mortality was only 16% (e7). The BARI study of 1996 (Bypass Angioplasty

Klinik und Poliklinik für Thorax-, Herz- und Gefäßchirurgie, Universitätsklinikum Münster: PD Dr. med. Klotz, Prof. Dr. med. Scheld

Revascularization Investigation), performed in the era of percutaneous transluminal angioplasty (PTCA), revealed a 5-year mortality of 10.7% (3). This study was the first to show a significant survival advantage for bypass surgery in comparison to PTCA for patients with diabetes mellitus. The internal thoracic artery was used in 82% of the operations in this study. In the Arterial Revascularization Therapies Study (ARTS), the 5-year mortality was still lower, at 7.6%. The *table* provides an overview of the various studies.

**Interventional techniques versus surgery**

Supplementing these survival studies of coronary artery bypass surgery, some of which were performed in an earlier era, most the major studies today compare interventional treatments with operative myocardial revascularization. The 8-year results of the Emory Angioplasty Versus Surgery Trial (EAST) were presented in 2000 (5). From 1983 onward, 392 patients were followed in a single center after randomization to transluminal angioplasty (PTCA) or surgery. The mortality of the patients who had undergone surgery was 17.3% at 8 years and did not differ significantly from that of the angioplasty patients (20.7%). The CABRI trial (Coronary Angioplasty versus Bypass Revascularization Investigation) was a European multicenter study of more than 1000 patients who were followed for 4 years (6). The overall mortality after surgery was 6.8% and did not differ significantly from the mortality after PTCA (12.5%). The special finding of this study, however, concerned patients with and without diabetes mellitus. In diabetic patients, the operative mortality after surgery was somewhat higher than in non-diabetics at 8.1%, but it was nevertheless significantly lower than the mortality of diabetic patients after PTCA, which was 17.8%. The Medicine, Angioplasty or Surgery Study (MASS-II) involved 611 patients randomized to receive pharmacotherapy, PTCA, or surgery (e8). No significant differences in survival were found among these 3 treatment groups in 5 years (12.6%, 16.2%, and 15.5%, respectively) (7). Nevertheless, bypass surgery was significantly better than interventional and conservative treatment with respect to the secondary endpoints (myocardial infarction, revascularization, and angina pectoris;  $p = 0.0026$ ). In a North American multicenter study with 8-year follow-up of more than 10 000 patients undergoing bypass surgery and more than 4000 undergoing PTCA, surgery was found to provide a significant survival advantage only to patients with three-vessel coronary disease (80.6% versus 76.6%) (8). The study with the longest follow-up was the German Angioplasty Bypass Surgery Investigation (GABI) (9), in which more than 300 patients were followed for 13 years after either bypass surgery or PTCA. The mortality was 35% after surgery and 41% after PTCA; the difference was not statistically significant. In this



The development of isolated coronary artery surgery in Germany from 1994 and 2006, divided into on-pump and off-pump procedures. With permission of the German Society for Thoracic and Cardiovascular Surgery.

**TABLE**

**Randomized studies comparing operative myocardial revascularization with percutaneous interventional procedures**

Study	Ref. No.	Year	Study design		Patients	Study interval	Mortality		Significance
							CABG	PCI	
<b>BARI</b>	(3)	1996	Multi-center	PTCA vs ACB	1 829 357*1	5 years	10.7 % 19.4 %	13.7 % 34.5 %	No p < 0.01
<b>EAST</b>	(5)	2000	Single-center	PTCA vs ACB	392	8 years	17.3 %	20.7 %	No
<b>CABRI</b>	(6)	2001	Multi-center	PTCA vs ACB	1 045 125*1	4 years	6.8 % 8.1 %	12.5 % 17.8 %	No p < 0.001
<b>AWESOME</b>	(23)	2002	Multi-center	PTCA vs ACB	1 343	5 years	20.0 %	19.0 %	No
<b>New England Study</b>	(8)	2005	Multi-center	PTCA vs ACB	14 493	8 years	19.4 %	23.4 %	p < 0.01*2
<b>GABI</b>	(9)	2005	Multi-center	PTCA vs ACB	359	13 years	35 %	41 %	No
<b>New York State Registry</b>	(25)	2005	Multi-center	PTCA vs ACB	37 212	3 years	10.7 %	15.6 %	p < 0.001
<b>MASS-II</b>	(7)	2007	Single-center	PTCA vs ACB	611	5 years	12.8 %	16.2 %	No
<b>SOS</b>	(24)	2002	Multi-center	BMS vs ACB	988	3 years	1.0 %	3.0 %	No
<b>ERACI-II</b>	(10)	2005	Multi-center	BMS vs ACB	450	5 years	7.2 %	11.6 %	No
<b>ARTS</b>	(4)	2005	Multi-center	BMS vs ACB	1 200	5 years	7.6 %	8.0 %	No

BARI = Bypass Angioplasty Revascularization Investigation; EAST = Emory Angioplasty Versus Surgery Trial; CABRI = Coronary Angioplasty Versus Bypass Revascularization Investigation; AWESOME, Angina With Extremely Serious Operative Mortality Evaluation; GABI = German Angioplasty Bypass Surgery Investigation; MASS = Medicine, Angioplasty, or Surgery Study; SOS = Stent or Surgery; ERACI = Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease; ARTS = Arterial Revascularization Therapies Study; ACB = Aortocoronary Bypass Operation; PTCA = percutaneous transluminal angioplasty; BMS = bare metal stent.  
\*1 Subgroup with diabetes mellitus.  
\*2 Only in 3-vessel CHD.


study, however, the internal thoracic artery was used for grafting in only 37% of all operations.

After the first bare metal stents (BMS) were implanted, the Argentine multicenter study ERACI-II randomized 450 patients into a BMS group and an operative group (10). No significant difference in survival was found after 5 years of follow-up (88.4% versus 92.8%). Alongside these single- and multicenter studies, meta-analyses yielded further important information: In a meta-analysis of 8 randomized studies with 1100 patients and a median follow-up interval of 5 years, bypass surgery was found to be superior to interventional therapy with respect to mortality, the rate of myocardial infarction, and the new development of angina pectoris (11). The weak point of this analysis, however, was the mixing together of minimally invasive and conventional surgery on the one hand, and of PTCA, BMS, and DES (drug-eluting stents) on the other. In a Cochrane analysis, bypass surgery was found to be significantly better than stent implantation after 3 years with respect to the need for new revascularization procedures, though no difference in mortality or the rate of myocardial infarction was detected (12).

Since the introduction of the newer drug-eluting stents, there has been as yet no major multicenter study comparing DES with surgical myocardial revascularization. 2 studies that are currently in progress, ARTS-II and ERACI-III, have shown no difference to date in the survival rates of surgery and DES (e9, e10). Questions have been raised about the validity of the comparison, because the ARTS-II study compares the DES group with the historical operative group from the ARTS-I study.

Only the results of single-center studies are currently available. Studies with a follow-up interval of 1 year revealed no significant differences between operative and interventional treatment (e11, e12). Nevertheless, in single-center studies with 2 or 3 years of follow-up, the rate of re-revascularization procedures after interventional treatment was significantly higher than that after surgery (2.8% versus 10.4% at 2 years, 2.6% versus 35.5% at 3 years), while the mortality and rate of myocardial infarction was no different (e13, e14). Studies involving only diabetic patients showed even more marked differences (e15, e16).

Multicenter studies that are now in progress are expected to shed more light on these issues. The multicenter, prospective SYNTAX study (Synergy Between Percutaneous




**Figure:** Off-pump operation without heart-lung machine. The suction cap holds the heart ventrally while the octopus stabilizer stabilizes the posterior interventricular branch (short white arrow). The anastomosis is performed with the radial artery (black arrow). The arrowhead points to a temporary ligature on the coronary vessel until the coronary shunt is introduced (long white arrow).

Coronary Intervention with Taxus [trade name of a paclitaxel-coated stent] and Cardiac Surgery) will involve 1500 patients with three-vessel coronary disease and accompanying main stem stenosis (e17); its results are expected to appear in 2012. The FREEDOM study (Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease) is intended to compare multiple DES implantation with bypass surgery in diabetic patients with multivessel disease; initial results are expected in 2010. Only a small amount of clinical data has been published to date regarding the latest generation of bio-absorbable drug-eluting stents. These have been successfully implanted in patients with acute myocardial infarction but were found to have a restenosis rate equal to that of BMS (13, e18).

### Off-pump versus on-pump

Off-pump coronary artery bypass grafting (OPCAB) is operative myocardial revascularization on the beating heart without the use of a heart-lung machine. Already in 2003, about 17% of all bypass operations in the United Kingdom and 21% in the U.S.A. were performed off pump. As shown in *diagram 1*, this operation is performed far less often in Germany. This surgical technique is made possible by mechanical aids that enable displacement (rotation) and local stabilization of the beating heart without hemodynamic compromise. So-called octopus stabilizers are used to hold the site of the anastomosis in place with mild suction (*figure*). Displacement of the heart, which is necessary for surgical access to the vessels of the posterior wall, is performed with a suction cap applied to the cardiac apex.

The theoretical advantages of this technique are its potentially lower morbidity and mortality because of its lesser invasiveness compared to on-pump surgery. To date, however, only a few large randomized studies on this topic have been published. The current prospective data show that the two techniques (bypass surgery with and without the use of a heart-lung machine) yield the same rate of postoperative survival in patients with multivessel disease (14, 15). Large prospective and retrospective studies have revealed, however, that patients undergoing "off pump" surgery have a slightly lower rate of




20-year survival after the use of both internal thoracic arteries (BITA, bilateral internal thoracic arteries) versus the left internal thoracic artery alone (SITA, single internal thoracic artery) (18).

postoperative stroke (16, e19). The rate of postoperative myocardial infarction or new angina pectoris was not different in the two groups (15, e20), yet 2 meta-analyses revealed a lower bypass patency rate for the off-pump technique (e21, e22). There is some evidence that older patients with additional cardiovascular risk factors stand to benefit the most from off-pump as compared to on-pump surgery (e20, e23, e24), but this must be interpreted in the light of the fact that patients whose intended off-pump procedure needs to be converted to an on-pump procedure intraoperatively are subject to a considerably higher mortality (e25). In selected patients, revascularization of the left anterior descending artery with the left internal thoracic artery can be performed with minimally invasive technique (MIDCAB, "minimally invasive direct coronary artery bypass") through a lateral approach (e26). This therapeutic option has proven its worth particularly in cases of isolated involvement of the LAD. In older patients with major comorbidity and diffuse multivessel disease, MIDCAB provides an opportunity to treat patients with a hybrid approach, in which the LAD is revascularized with this minimally invasive technique and the remaining affected vessels are revascularized with interventional procedures (e27).

This special topic will be dealt with in another review article in this journal in the near future and will therefore not be discussed any further here.

**Total arterial revascularization**

Although the standard method of operative revascularization to date has involved the use of the left internal thoracic artery in combination with venous grafts from the leg, complete arterial bypass grafting is now being performed more and more commonly. The occlusion rate of venous grafts after 10 years is circa 50%, largely because of accelerated atherosclerotic degeneration and intimal proliferation. The more common surgical technique involves anastomosis of the left internal thoracic artery in situ to the LAD. It was shown as early as 1986 that bypass grafts remain patent for a much longer time if the left internal thoracic artery is used rather than a venous graft (97% versus 50% at 10 years) (2). Over the last 20 years, therefore, arteries have been used more commonly, either for total arterial revascularization or in combination with venous bypasses. Although alternative arterial bypass grafts from the abdominal area (inferior epigastric artery, gastroepiploic artery) have not been adopted in widespread use because of the need for a separate surgical opening, the use of both of the internal thoracic arteries simultaneously has been found to provide a significant survival advantage (diagram 2) (17, 18, e28). As only 2 coronary vessels can be revascularized with the two internal thoracic arteries, the radial artery is often used at present as an additional graft source (19, e29). The patency rate of bypasses with this




The diagram reveals the marked increase in patients over 80 years of age undergoing cardiac surgery in recent years. Reproduced with permission from the "Brucknerberger Herzbericht 2005."

vessel, however, is not any better than that of bypasses with the internal thoracic artery; this is primarily because the radial artery usually is not used to revascularize the LAD (e30, e31). However the patency rate is significantly better compared to venous bypasses (19, e32). The major factor conferring a long-term advantage with respect to patency appears to be a skeletonizing technique, rather than a pedicle graft technique, for the preparation of the vessel (e33). In the former technique, only the vessel itself is dissected free; in the latter, the vessel is removed together with the accompanying veins and adipose tissue.

**Surgery in older patients**

The number of older patients undergoing cardiac surgery has risen steadily over the past decade (*diagram 3*); the number of patients over 80 years of age, for example, has risen from 2.3% in 1994 to 8.5% in 2000 (e34). This raises the question whether there is any associated change in morbidity and mortality after surgical myocardial revascularization. In a comparative study published in 1999, Carver et al. showed that mortality rises significantly with age (*diagram 4*) (20). In 2000, an American multicenter study revealed that the in-hospital mortality of patients over 80 years of age was with 8.3% significantly higher than that of younger patients with 3.0% (e35). Above all, the rate of perioperative stroke was markedly higher in elderly patients. In view of the higher mortality of conventional on-pump bypass surgery in this patient group, the question of whether off-pump surgery confers any advantage in this regard was addressed. A meta-analysis published in 1996, involving 4,921 patients, showed that the mortality and the rate of postoperative development of atrial fibrillation were significantly lower in patients over 70 years of age undergoing off-pump rather than on-pump coronary bypass surgery (21). In this study, however, the incidence of stroke was no different in the on-pump and off-pump groups. A similar study by Jensen et al. revealed no difference in cognitive function 3 month after surgery in patients over 76 years of age who had undergone either on-pump or off-pump procedures (e36). On the other hand, another meta-analysis involving 4,475 patients over age 70 revealed a considerably lower stroke rate in patients who had undergone off-pump as compared with conventional bypass surgery (1% versus 3%) (22). In a large study with data collected by the New York State Department of Health on more than 88,000 patients, patients over age 80 had significantly longer hospital stays (14.1 versus 11.5 days) and increased mortality (5.1% versus 2.7%) mainly because of postoperative respiratory insufficiency (e37). In another, similar study, patients over age 80 had significantly higher mortality (8% versus 2%) and a significantly higher length of hospital stay (8.7 versus 6.7 days), as well as



The diagram reveals the increased mortality associated with advanced age and emergency surgery (20).

significantly more frequent neurological, pulmonary, and renal complications (e38). Nevertheless, despite all of these risks, patients who have been successfully treated with surgery in this age group have a considerably better quality of life than comparably aged patients who do not undergo surgery, with no difference in life expectancy (e39, e40).

**Summary**

The use of the heart-lung machine remains the gold standard for aortocoronary bypass surgery. Surgical methods not involving extracorporeal circulation have failed to fulfill some of the expectations placed on them. Most studies have revealed no advantage with respect to survival or complications compared to conventionally performed (on-pump) surgery. The data on bypass graft patency after off-pump surgery should be interpreted critically and with caution. Nonetheless, because conventional surgery is now being performed with markedly higher risks than before because of the increasing number of elderly patients, it is perhaps precisely in this patient group that off-pump surgery will find its most useful application. There are not yet enough data to permit a reliable comparison with interventional stent implantation and the use of the new, medication-coated stents. The results of larger studies comparing stent implantation with total arterial revascularization will not be available until a few years from now.

The use of complete arterial bypass revascularization (the two internal thoracic arteries and the radial artery) can be expected to yield a further improvement in long-term bypass patency.

**Conflict of Interest Statement**

The authors state that they have no conflict of interest as defined by the guidelines of the International Committee of Medical Journal Editors.

Manuscript received on 9 May 2007; final version accepted on 23 July 2007.

Translated from the original German by Ethan Taub, M.D.

**REFERENCES**

For e-references please refer to the additional references listed below.

1. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. *Circulation* 1983; 68: 939–50.
2. Loop FD, Lytle BW, Cosgrove DM et al.: Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. *N Engl J Med* 1986; 314: 1–6.
3. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI). *N Engl J Med* 1996; 335: 217–25.

4. Serruys PW, Ong AT, van Herwerden LA et al.: Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. *J Am Coll Cardiol* 2005; 46: 575–81.
5. King SB, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS: Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). *J Am Coll Cardiol* 2000; 35: 1116–21.
6. Kurbaan AS, Bowker TJ, Ilsley CD, Sigwart U, Rickards AF: Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. *Am J Cardiol* 2001; 87: 947–50.
7. Hueb W, Lopes NH, Gersh BJ et al.: Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation* 2007; 115: 1082–9.
8. Malenka DJ, Leavitt BJ, Hearne MJ et al.: Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. *Circulation* 2005; 112: 371–6.
9. Kaehler J, Koester R, Billmann W et al.: 13-year follow-up of the German angioplasty bypass surgery investigation. *Eur Heart J* 2005; 26: 2148–53.
10. Rodriguez AE, Baldi J, Fernandez PC et al.: Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). *J Am Coll Cardiol* 2005; 46: 582–8.
11. Boodhwani M, Rubens FD, Sellke FW, Mesana TG, Ruel M: Mortality and myocardial infarction following surgical versus percutaneous revascularization of isolated left anterior descending artery disease: a meta-analysis. *Eur J Cardiothorac Surg* 2006; 29: 65–70.
12. Bakhai A, Hill RA, Dundar Y, Dickson R, Walley T: Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes. *Cochrane Database Syst Rev* 2005; 1: CD004588.
13. Erbel R, Di MC, Bartunek J et al.: Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomized multicentre trial. *Lancet* 2007; 369: 1869–75.
14. Legare JF, Buth KJ, King S et al.: Coronary bypass surgery performed off pump does not result in lower in-hospital morbidity than coronary artery bypass grafting performed on pump. *Circulation* 2004; 109: 887–92.
15. Khan NE, De SA, Mister R et al.: A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery. *N Engl J Med* 2004; 350: 21–8.
16. Sellke FW, DiMaio JM, Caplan LR et al.: Comparing on-pump and off-pump coronary artery bypass grafting: numerous studies but few conclusions: a scientific statement from the American Heart Association council on cardiovascular surgery and anesthesia in collaboration with the interdisciplinary working group on quality of care and out-comes research. *Circulation* 2005; 111: 2858–64.
17. Rankin JS, Tuttle RH, Wechsler AS, Teichmann TL, Glower DD, Califf RM: Techniques and benefits of multiple internal mammary artery bypass at 20 years of follow-up. *Ann Thorac Surg* 2007; 83: 1008–15.
18. Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, Cosgrove DM: The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. *Ann Thorac Surg* 2004; 78: 2005–12.
19. Desai ND, Naylor CD, Kiss A et al.: Impact of patient and target-vessel characteristics on arterial and venous bypass graft patency: in-sight from a randomized trial. *Circulation* 2007; 115: 684–91.
20. Craver JM, Puskas JD, Weintraub WW et al.: 601 octogenarians undergoing cardiac surgery: outcome and comparison with younger age groups. *Ann Thorac Surg* 1999; 67: 1104–10.
21. Panesar SS, Thakrar R, Athanasiou T, Sheikh A: Comparison of reports of randomized controlled trials and systematic reviews in surgical journals: literature review. *J R Soc Med* 2006; 99: 470–2.
22. Athanasiou T, Al-Ruzzeh S, Kumar P et al.: Off-pump myocardial revascularization is associated with less incidence of stroke in elderly patients. *Ann Thorac Surg* 2004; 77: 745–53.
23. Morrison DA, Sethi G, Sacks J et al.: Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: The VA AWESOME multicenter registry: comparison with the randomized clinical trial. *J Am Coll Cardiol* 2002; 39: 266–73.
24. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomized controlled trial. *Lancet* 2002; 360: 965–70.
25. Hannan EL, Racz MJ, Walford G et al.: Long-term outcomes of coronary-artery by-pass grafting versus stent implantation. *N Engl J Med* 2005; 352: 2174–83.

**ADDITIONAL REFERECNES**

- e1. Vineberg AM, Miller WD: An experimental study of the physiological role of an anastomosis between the left coronary circulation and the left internal mammary artery implanted in the left ventricular myocardium. *Surg Forum* 1950; 294–9.
- e2. Murray G, Hilario J, Porcheron R, Roschlau W: Surgery of coronary heart disease. *Angiology* 1953; 4: 526–31.
- e3. Boettcher W, Merkle F, Weitkemper HH: History of extracorporeal circulation: the invention and modification of blood pumps. *J Extra Corpor Technol* 2003; 35: 184–91.
- e4. Favaloro RG: Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. *Ann Thorac Surg* 1968; 5: 334–9.

- e5. Green GE: Rate of blood flow from the internal mammary artery. *Surgery* 1971; 70: 809–13.
- e6. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. *N Engl J Med* 1984; 311: 1333–9.
- e7. Yusuf S, Zucker D, Chalmers TC: Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2. *Online J Curr Clin Trials* 1994; Doc No 145: 3987.
- e8. Hueb W, Soares PR, Gersh BJ et al.: The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. *J Am Coll Cardiol* 2004; 43: 1743–51.
- e9. Rodriguez AE, Mieres J, Fernandez-Pereira C et al.: Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. *J Am Coll Cardiol* 2006; 47: 205–7.
- e10. Serruys PW, Lemos PA, van Hout BA: Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). *Heart* 2004; 90: 995–8.
- e11. Chieffo A, Morici N, Maisano F et al.: Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. *Circulation* 2006; 113: 2542–7.
- e12. Lee MS, Kapoor N, Jamal F et al.: Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2006; 47: 864–70.
- e13. Yang ZK, Shen WF, Zhang RY et al.: Coronary artery bypass surgery versus percutaneous coronary intervention with drug-eluting stent implantation in patients with multivessel coronary disease. *J Interv Cardiol* 2007; 20: 10–6.
- e14. Palmerini T, Marzocchi A, Marzocchini C et al.: Comparison between coronary angioplasty and coronary artery bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna Registry). *Am J Cardiol* 2006; 98: 54–9.
- e15. Ben-Gal Y, Moshkovitz Y, Neshet N et al.: Drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. *Ann Thorac Surg* 2006; 82: 1692–7.
- e16. Lee MS, Jamal F, Kedia G et al.: Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. *Int J Cardiol* 2007.
- e17. Ong AT, Serruys PW, Mohr FW et al.: The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. *Am Heart J* 2006; 151: 1194–204.
- e18. Lee CH, Lim J, Low A et al.: Sirolimus-Eluting, Bioabsorbable Polymer-Coated Constant Stent (Cura(R)) in Acute ST-Elevation Myocardial Infarction: A Clinical and Angiographic Study (CURAMI Registry). *J Invasive Cardiol* 2007; 19: 182–5.
- e19. Sabik JF, Blackstone EH, Lytle BW, Houghtaling PL, Gillinov AM, Cosgrove DM: Equivalent midterm outcomes after off-pump and on-pump coronary surgery. *J Thorac Cardiovasc Surg* 2004; 127: 142–8.
- e20. Racz MJ, Hannan EL, Isom OW et al.: A comparison of short- and long-term outcomes after off-pump and on-pump coronary artery bypass graft surgery with sternotomy. *J Am Coll Cardiol* 2004; 43: 557–64.
- e21. Lim E, Drain A, Davies W, Edmonds L, Rosengard BR: A systematic review of randomized trials comparing revascularization rate and graft patency of off-pump and conventional coronary surgery. *J Thorac Cardiovasc Surg* 2006; 132: 1409–13.
- e22. Takagi H, Tanabashi T, Kawai N, Kato T, Umemoto T: Off-pump coronary artery bypass sacrifices graft patency: meta-analysis of randomized trials. *J Thorac Cardiovasc Surg* 2007; 133: e2–3.
- e23. Magee MJ, Coombs LP, Peterson ED, Mack MJ: Patient selection and current practice strategy for off-pump coronary artery bypass surgery. *Circulation* 2003; 108 Suppl 1: I19–14.
- e24. Al-Ruzzeh S, Ambler G, Asimakopoulos G et al.: Off-Pump Coronary Artery Bypass (OPCAB) surgery reduces risk-stratified morbidity and mortality: a United Kingdom Multi-Center Comparative Analysis of Early Clinical Outcome. *Circulation* 2003; 108 Suppl 1: II1–II8.
- e25. Patel NC, Patel NU, Loulmet DF, McCabe JC, Subramanian VA: Emergency conversion to cardiopulmonary bypass during attempted off-pump revascularization results in increased morbidity and mortality. *J Thorac Cardiovasc Surg* 2004; 128: 655–61.
- e26. Kettering K, Dapunt O, Baer FM: Minimally invasive direct coronary artery bypass grafting: a systematic review. *J Cardiovasc Surg* 2004; 45: 255–64.
- e27. Amodeo VJ, Donias HW, Dancona G, Hoover EL, Karamanoukian HL: The hybrid approach to coronary artery revascularization: minimally invasive direct coronary artery bypass with percutaneous coronary intervention. *Angiology* 2002; 53: 665–9.
- e28. Damgaard S, Steinbruchel DA, Kjaergard HK: An update on internal mammary artery grafting for coronary artery disease. *Curr Opin Cardiol* 2005; 20: 521–4.
- e29. Gardner TJ: Searching for the second-best coronary artery bypass graft: is it the radial artery? *Circulation* 2007; 115: 678–80.
- e30. Crusco F, Antoniella A, Papa V et al.: Midterm follow-up of patients receiving radial artery as coronary artery bypass grafts using 16-detectorrow CT coronary angiography. *Radiol Med (Torino)* 2007; 12: 538–49.
- e31. Bonacchi M, Prifti E, Maiani M et al.: Perioperative and clinical-angiographic late outcome of total arterial myocardial revascularization according to different composite original graft techniques. *Heart Vessels* 2006; 21: 69–77.

- e32. Desai ND, Cohen EA, Naylor CD, Fremes SE: A randomized comparison of radialartery and saphenous-vein coronary bypass grafts. *N Engl J Med* 2004; 351: 2302–9.
- e33. Miyagi N, Oshima N, Shirai T, Sunamori M: Skeletonized harvesting improves the early-term and mid-term perfect patency of a radial artery graft. *Jpn J Thorac Cardiovasc Surg* 2006; 54: 472–6.
- e34. DGTHG: Leistungsstatistik der Deutschen Gesellschaft für Thorax-, Herz- und Gefäßchirurgie, 2005.
- e35. Alexander KP, Anstrom KJ, Muhlbaier LH et al.: Outcomes of cardiac surgery in patients > or = 80 years: results from the National Cardiovascular Network. *J Am Coll Cardiol* 2000; 35: 731–8.
- e36. Jensen BO, Hughes P, Rasmussen LS, Pedersen PU, Steinbruchel DA: Cognitive outcomes in elderly high-risk patients after off-pump versus conventional coronary artery bypass grafting: a randomized trial. *Circulation* 2006; 113: 2790–5.
- e37. Bardakci H, Cheema FH, Topkara VK et al.: Discharge to home rates are significantly lower for octogenarians undergoing coronary artery bypass graft surgery. *Ann Thorac Surg* 2007; 83: 483–9.
- e38. Johnson WM, Smith JM, Woods SE, Hendy MP, Hiratzka LF: Cardiac surgery in octogenarians: does age alone influence outcomes? *Arch Surg* 2005; 140: 1089–93.
- e39. Peterson ED, Cowper PA, Jollis JG et al.: Outcomes of coronary artery bypass graft surgery in 24 461 patients aged 80 years or older. *Circulation* 1995; 92: 1185–91.
- e40. Potger KC, McMillan D, Connolly T, Southwell J, Dando H, O'Shaughnessy K: Coronary artery bypass grafting: an off-pump versus on-pump review. *J Extra Corpor Technol* 2002; 34: 260–6.

---

**Corresponding author**

PD Dr. med. Stefan Klotz  
 Klinik und Poliklinik für Thorax-, Herz- und Gefäßchirurgie  
 Universitätsklinikum Münster  
 Albert-Schweitzer-Str. 33  
 48149 Münster, Germany  
[stefan.klotz@ukmuenster.de](mailto:stefan.klotz@ukmuenster.de)